Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


       2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Active Pharmaceutical Ingredients  TAJ PHARMACEUTICALS LIMITED

Oseltamivir Phosphate Manufacturers in India Suppliers Oseltamivir Phosphate Exporters Distributors Oseltamivir Phosphate api active pharmaceuticals ingredients Oseltamivir Phosphate manufacturers Side Effects bulk drugs raw material Oseltamivir Phosphate companies Side Effects Importers Oseltamivir Phosphate Oseltamivir Phosphate Exporters Oseltamivir Phosphate exporters FDA Oseltamivir Phosphate DMF Symptoms Generic Taj Pharmaceuticals Ltd.

Pharmaceuticals API Manufacturer Oseltamivir Phosphate, Oseltamivir Phosphate manufacturer India, Oseltamivir Phosphate product, Oseltamivir Phosphate products, Api preparation, Certificate of Analysis API manufacturer product, Oseltamivir Phosphate anti ulcer product, Certificate of Origin COA Oseltamivir Phosphate COS Oseltamivir Phosphate, pharmaceutical generic, pharmaceutical drug, medical, Oseltamivir Phosphate pharma healthcare, pharma patents, contract MSDS manufacturing Trader Oseltamivir Phosphate pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Oseltamivir Phosphate expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Oseltamivir Phosphate DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Oseltamivir Phosphate ingredients, api, HIV Oseltamivir Phosphate, tablets, capsules, syrup & protein Oseltamivir Phosphate powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Oseltamivir Phosphate gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Oseltamivir Phosphate WHO, UKMHRA Approval

   PRODUCT LIST
   Home
   API >>
   Pharmaceuticals API List >>>
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 
   

Swine influenza (also called H1N1 flu, swine flu, hog flu, and pig flu) is an infection by any one of several types of swine influenza virus. Swine influenza virus (SIV) is any strain of the influenza family of viruses that is endemic in pigs.  As of 2009, the known SIV strains include influenza C and the subtypes of influenza A known as H1N1, H1N2, H3N1, H3N2, and H2

More API manufacturing at Taj

Oseltamivir Phosphate  

Phenyl Propanolamine

Phenylephrine

Etafedrine
Theophylline
Tramadol
Methylphenidate
Morphine HCl
Morphine sulphate
Ephedrine (EPH)
Pseudoephedrine hydrochloride
Codeine base
Codeine phosphate hemihydrate
Zolpidem Tartrate
Caffeine


Ciprofloxacin HCl Oseltamivir Phosphate


Ciprofloxacin HCl Oseltamivir Phosphate


Ciprofloxacin HCl

Oseltamivir Phosphate


Ciprofloxacin HCl Oseltamivir Phosphate

 
HOME >> API >> API List 2 >> Oseltamivir Phosphate


 

Oseltamivir Phosphate ( INN) pdf api
Oseltamivir Phosphate CAS No.: 204255-11-8
Product name: Oseltamivir phosphate
Chemical name: Ethyl(3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate phosphate
CAS No.: 204255-11-8
Molecular formula : C16H28N2O4.H3PO4
Assay: 97%min



Product Description

Appearance: White to off-white crystalline powder
Purity(HPLC): 99%min
Melting Point : 201-203degree
Optical Rotation: -34.0- -38.0degree
Moisture: 0.30%max
Heavy metals: 20ppm max
Residue on ignition: 0.1%max
Impurity Ro-1637: 0.03%max
Any other individual impurity: 0.50%max
Total impurities: 1.0%max

Productivity: 500kg/month


Mode of action

CAS No.:	204255-11-8Oseltamivir is a neuraminidase inhibitor, serving as a competitive inhibitor towards sialic acid, found on the surface proteins of normal host cells. By blocking the activity of the neuraminidase, Oseltamivir prevents new viral particles from being released by infected cells.

Resistance

As with other antivirals, resistance to the agent was expected with widespread use of oseltamivir, though the emergence of resistant viruses was expected to be less frequent than with amantadine or rimantadine. The resistance rate reported during clinical trials up to July 2004 was 0.33% in adults, 4.0% in children, and 1.26% overall. Mutations conferring resistance are single amino acid residue substitutions in the neuraminidase enzyme.
H3N2
As with other antivirals, resistance to the agent was expected with widespread use of oseltamivir, though the emergence of resistant viruses was expected to be less frequent than with amantadine or rimantadine. The resistance rate reported during clinical trials up to July 2004 was 0.33% in adults, 4.0% in children, and 1.26% overall. Mutations conferring resistance are single amino acid residue substitutions in the neuraminidase enzyme.
Mutant H3N2 influenza A virus isolates resistant to oseltamivir were found in 18% of a group of 50 Japanese children treated with oseltamivir.This rate was similar to another study where resistant isolates of H1N1 influenza virus were found in 16.3% of another cohort of Japanese children. Several explanations were proposed by the authors of the studies for the higher-than-expected resistance rate detected. First, children typically have a longer infection period, giving a longer time for resistance to develop. Second, Kiso et al. claim to have used more rigorous detection techniques than previous studies.

H5N1 avian influenza

High-level resistance has been detected in one girl suffering from H5N1 avian influenza in Vietnam. She was being treated with oseltamivir at time of detection. de Jong et al. (2005) describe resistance development in two more Vietnamese patients suffering from H5N1, and compare their cases with six others. They suggest that the emergence of a resistant strain may be associated with a patient's clinical deterioration. They also note that the recommended dosage of oseltamivir does not always completely suppress viral replication, a situation that could favor the emergence of resistant strains. Moscona (2005) gives a good overview of the resistance issue, and says that personal stockpiles of Tamiflu could lead to under-dosage and thus the emergence of resistant strains of H5N1.

Resistance is of concern in the scenario of an influenza pandemic (Wong and Yuen 2005), and may be more likely to develop in avian influenza than seasonal influenza due to the potentially longer duration of infection by novel viruses. Kiso et al. suggest that "a higher prevalence of resistant viruses should be expected" during a pandemic.

Note: Veterinary use
There have been anecdotal reports of oseltamivir reducing disease severity and hospitalization time in canine parvovirus infection. The drug may limit the ability of the virus to invade the crypt cells of the small intestine and decrease gastrointestinal bacteria colonization and toxin production.


There have been anecdotal reports of oseltamivir reducing disease severity and hospitalization time in canine parvovirus infection. The drug may limit the ability of the virus to invade the crypt cells of the small intestine and decrease gastrointestinal bacteria colonization and toxin production.

 
          text logo
  PDF DOWNLOAD      WORD DOCUMENT    TEXT DOCUMENT

 

Product Enquiry Product Quotation Sample Request Place Your Order    
Product Enquiry Product Quotation Sample Request Place Your Order    

        
>>   New Product Introduced : Oseltamivir Phosphate, Phenyl Propanolamine, Phenylephrine, Etafedrine


   Swine influenza (also called H1N1 flu, swine flu, hog flu, and pig flu) is an infection by any one of several types of swine influenza virus. Swine influenza virus (SIV) is any strain of the influenza family of viruses that is endemic in pigs.  As of 2009, the known SIV strains include influenza C and the subtypes of influenza A known as H1N1, H1N2, H3N1, H3N2, and H2

Article : Swine influenza
Swine influenza
(also called H1N1 flu, swine flu, hog flu, and pig flu) is an infection by any one of several types of swine influenza virus. Swine influenza virus (SIV) is any strain of the influenza family of viruses that is endemic in pigs.  As of 2009, the known SIV strains include influenza C and the subtypes of influenza A known as H1N1, H1N2, H3N1, H3N2, and H2N3.

Swine influenza virus is common throughout pig populations worldwide. Transmission of the virus from pigs to humans is not common and does not always lead to human influenza, often resulting only in the production of antibodies in the blood. If transmission does cause human influenza, it is called zoonotic swine flu. People with regular exposure to pigs are at increased risk of swine flu infection. The meat of an infected animal poses no risk of infection when properly cooked.

During the mid-20th century, identification of influenza subtypes became possible, allowing accurate diagnosis of transmission to humans. Since then, only 50 such transmissions have been confirmed. These strains of swine flu rarely pass from human to human. Symptoms of zoonotic swine flu in humans are similar to those of influenza and of influenza-like illness in general, namely chills, fever, sore throat, muscle pains, severe headache, coughing, weakness and general discomfort.

Taj pharmaceuticals API Logo

Oseltamivir Phosphate

More Api at Taj Pharmaceuticals Ltd.

Alfuzosin

Oseltamivir Phosphate

 Amlodipine Besylate

Aripiprazole

Atorvastatin Calcium

Candesartan Cilaxetil

Cefdinir

Cetirizine Dihydrochloride

Ciprofloxacin HCl

Dextromethorphan Base

Diltiazem HCl

Domperidone Base

Domperidone Maleate

Doxazosin Mesylate

 Duloxetine HCl

Dutasteride

Enalapril Maleate

Esomeprazole Magnesium

Famotidine

Fexofenadine HCl

Fluconazole

Fluoxetine HCl

Galantamine HBr

Ibuprofen

Caffeine

Copyright Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

 

taj group logo
2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals  Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals  Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.